Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Physiol Endocrinol Metab ; 291(3): E449-59, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16608886

ABSTRACT

To determine the effect of nonesterified fatty acids (NEFA) on glucagon action, glucagon was infused intraportally (1.65 ng.min(-1).kg(-1)) for 3 h into 18-h-fasted, pancreatic-clamped conscious dogs in the presence [NEFA + glucagon (GGN)] or absence (GGN) of peripheral Intralipid plus heparin infusion. Additionally, hyperglycemic (HG), hyperglycemic-hyperlipidemic (NEFA + HG), and glycerol plus glucagon (GLYC + GGN) controls were studied. Arterial plasma glucagon concentrations rose equally in GGN, NEFA + GGN, and GLYC + GGN but remained basal in hyperglycemic controls. Peripheral infusions of Intralipid and heparin increased arterial plasma NEFA concentrations equally in NEFA + GGN and NEFA + HG and did not change in other protocols. After 15 min, glucagon infusion resulted in a rapid, brief increase in net hepatic glycogenolysis (NHGLY, mg.min(-1).kg(-1)) of approximately 6.0 in GGN and GLYC + GGN but only increased by 3.8 +/- 1.3 in NEFA + GGN. Thus increases in NHGLY, and consequently net hepatic glucose output (NHGO), were blunted by 40%, with no difference between the groups in the last 2.5 h of the study. NHGO and NHGLY did not significantly change in HG and NEFA + HG. Net hepatic gluconeogenic flux did not change in GGN, GLYC + GGN, or HG. However, Intralipid and heparin infusion resulted in similar increases in net hepatic gluconeogenic flux in NEFA + GGN and NEFA + HG. Thus elevated NEFA limit the initial increase in glucagon-stimulated HGO by blunting glycogenolysis, without having any effect on the gluconeogenic or glycogenolytic contributions or NHGO thereafter.


Subject(s)
Fatty Acids, Nonesterified/pharmacology , Glucagon/pharmacology , Glucose/metabolism , Liver/metabolism , 3-Hydroxybutyric Acid/blood , 3-Hydroxybutyric Acid/metabolism , Acetoacetates/blood , Acetoacetates/metabolism , Amino Acids/blood , Amino Acids/metabolism , Animals , Blood Glucose/metabolism , Cyclic AMP/metabolism , Dogs , Fat Emulsions, Intravenous/pharmacology , Fatty Acids, Nonesterified/blood , Fatty Acids, Nonesterified/metabolism , Glucagon/blood , Gluconeogenesis/drug effects , Glucose/pharmacology , Glucose Clamp Technique , Glycerol/blood , Glycerol/pharmacology , Glycogenolysis/drug effects , Heparin/pharmacology , Hyperglycemia/blood , Hyperglycemia/metabolism , Insulin/blood , Lactic Acid/blood , Lactic Acid/metabolism , Liver/drug effects
2.
Metabolism ; 53(7): 933-41, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15254890

ABSTRACT

The role of renal glucose production after an overnight fast and in response to different hormonal conditions has been debated. The aim of this study was to determine whether hyperglycemia, glucagon, or epinephrine can affect renal glucose production. In 18-hour fasted conscious dogs a pancreatic clamp initially fixed insulin and glucagon at basal levels, following which 1 of 4 protocols was instituted. In G+E glucagon (1.5 ng. kg(-1). min(-1); portally) and epinephrine (50 ng. kg(-1). min(-1); peripherally) were increased, in G glucagon was increased alone, in E epinephrine was increased alone, and in C neither were increased. In G, E, and C, glucose was infused to match the hyperglycemia in G+E (approximately 250 mg/dL). The average net renal glucose output during the last 2 hours was not different from the basal values in any group. Furthermore, the changes in unidirectional renal glucose production were not significantly different among groups. Therefore, after an overnight fast in the conscious dog, the kidneys do not significantly contribute to overall glucose production or respond to glucagon or epinephrine.


Subject(s)
Epinephrine/pharmacology , Glucagon/pharmacology , Glucose/metabolism , Hyperglycemia/metabolism , Kidney/metabolism , Amino Acids/blood , Animals , Blood Glucose/metabolism , Dogs , Epinephrine/blood , Female , Glucagon/blood , Gluconeogenesis/drug effects , Glucose Clamp Technique , Insulin/blood , Kidney/drug effects , Lactic Acid/blood , Lactic Acid/metabolism , Male
3.
Am J Physiol Gastrointest Liver Physiol ; 286(4): G627-34, 2004 Apr.
Article in English | MEDLINE | ID: mdl-14656711

ABSTRACT

The rate of liver glucokinase (GK) translocation from the nucleus to the cytoplasm in response to intraduodenal glucose infusion and the effect of physiological rises of plasma glucose and/or insulin on GK translocation were examined in 6-h-fasted conscious rats. Intraduodenal glucose infusion (28 mg.kg(-1).min(-1) after a priming dose at 500 mg/kg) elevated blood glucose levels (mg/dl) in the artery and portal vein from 90 +/- 3 and 87 +/- 3 to 154 +/- 4 and 185 +/- 4, respectively, at 10 min. At 120 min, the levels had decreased to 133 +/- 6 and 156 +/- 5, respectively. Plasma insulin levels (ng/ml) in the artery and the portal vein rose from 0.7 +/- 0.1 and 1.8 +/- 0.3 to 11.8 +/- 1.5 and 20.2 +/- 2.0 at 10 min, respectively, and 12.4 +/- 3.1 and 18.0 +/- 4.8 at 30 min, respectively. GK was rapidly exported from the nucleus as determined by measuring the ratio of the nuclear to the cytoplasmic immunofluorescence (N/C) of GK (2.9 +/- 0.3 at 0 min to 1.7 +/- 0.2 at 10 min, 1.5 +/- 0.1 at 20 min, 1.3 +/- 0.1 at 30 min, and 1.3 +/- 0.1 at 120 min). When plasma glucose (arterial; mg/dl) and insulin (arterial; ng/ml) levels were clamped for 30 min at 93 +/- 7 and 0.7 +/- 0.1, 81 +/- 5 and 8.9 +/- 1.3, 175 +/- 5 and 0.7 +/- 0.1, or 162 +/- 5 and 9.2 +/- 1.5, the N/C of GK was 3.0 +/- 0.5, 1.8 +/- 0.1, 1.5 +/- 0.1, and 1.2 +/- 0.1, respectively. The N/C of GK regulatory protein (GKRP) did not change in response to the intraduodenal glucose infusion or the rise in plasma glucose and/or insulin levels. The results suggest that GK but not GKRP translocates rapidly in a manner that corresponds with changes in the hepatic glucose balance in response to glucose ingestion in vivo. Additionally, the translocation of GK is induced by the postprandial rise in plasma glucose and insulin.


Subject(s)
Blood Glucose/metabolism , Duodenum/physiology , Glucokinase/metabolism , Glucose/pharmacology , Insulin/blood , Liver/enzymology , Animals , Blotting, Western , Catheterization, Peripheral , Glucose/administration & dosage , Immunohistochemistry , Intubation, Gastrointestinal , Liver Circulation/drug effects , Male , Microscopy, Confocal , Protein Transport , Rats , Rats, Sprague-Dawley , Renal Circulation/drug effects
4.
Science ; 301(5631): 370-3, 2003 Jul 18.
Article in English | MEDLINE | ID: mdl-12869762

ABSTRACT

Glucokinase (GK) plays a key role in whole-body glucose homeostasis by catalyzing the phosphorylation of glucose in cells that express this enzyme, such as pancreatic beta cells and hepatocytes. We describe a class of antidiabetic agents that act as nonessential, mixed-type GK activators (GKAs) that increase the glucose affinity and maximum velocity (Vmax) of GK. GKAs augment both hepatic glucose metabolism and glucose-induced insulin secretion from isolated rodent pancreatic islets, consistent with the expression and function of GK in both cell types. In several rodent models of type 2 diabetes mellitus, GKAs lowered blood glucose levels, improved the results of glucose tolerance tests, and increased hepatic glucose uptake. These findings may lead to the development of new drug therapies for diabetes.


Subject(s)
Carrier Proteins , Diabetes Mellitus, Type 2/drug therapy , Glucokinase/metabolism , Glucose/metabolism , Insulin/metabolism , Islets of Langerhans/drug effects , Liver/drug effects , Thiazoles/pharmacology , Adaptor Proteins, Signal Transducing , Allosteric Regulation , Animals , Blood Glucose/metabolism , Diabetes Mellitus, Type 2/metabolism , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Enzyme Activation , Enzyme Activators/chemistry , Enzyme Activators/pharmacology , Glucose Tolerance Test , Homeostasis , Humans , Hypoglycemic Agents/chemistry , Hypoglycemic Agents/pharmacology , Insulin/blood , Insulin Secretion , Intracellular Signaling Peptides and Proteins , Islets of Langerhans/metabolism , Keto Acids/metabolism , Liver/metabolism , Liver Glycogen/biosynthesis , Male , Mice , Mice, Inbred C57BL , Mice, Obese , Proteins/metabolism , Proteins/pharmacology , Rats , Rats, Wistar , Recombinant Proteins/metabolism , Stereoisomerism , Thiazoles/chemistry
5.
Am J Physiol Endocrinol Metab ; 285(3): E534-44, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12736160

ABSTRACT

It was previously shown that glucagon and epinephrine have additive effects on both gluconeogenic and glycogenolytic flux. However, the changes in gluconeogenic substrates may have been limiting and thus may have prevented a synergistic effect on gluconeogenesis and a reciprocal inhibitory effect on glycogenolysis. Thus the aim of the present study was to determine if glucagon has a greater gluconeogenic and a smaller glycogenolytic effect in the presence of both epinephrine and clamped gluconeogenic precursors. Two groups (Epi and G + Epi + P) of 18-h-fasted conscious dogs were studied. In Epi, epinephrine was increased, and in G + Epi + P, glucagon and epinephrine were increased. Gluconeogenic precursors (lactate and alanine) were infused in G + Epi + P to match the rise that occurred in Epi. Insulin and glucose levels were also controlled and were similar in the two groups. Epinephrine and precursor administration increased glucagon's effect on gluconeogenesis (4.5-fold; P < 0.05) and decreased glucagon's effect on glycogenolysis (85%; P = 0.08). Thus, in the presence of both hormones, and when the gluconeogenic precursor supply is maintained, gluconeogenic flux is potentiated and glycogenolytic flux is inhibited.


Subject(s)
Alanine/pharmacology , Epinephrine/pharmacology , Glucagon/metabolism , Lactic Acid/pharmacology , Sympathomimetics/pharmacology , Animals , Blood Glucose/metabolism , Blood Pressure , Dogs , Drug Synergism , Fatty Acids, Nonesterified/blood , Female , Gluconeogenesis/drug effects , Gluconeogenesis/physiology , Glycerol/blood , Glycogen/metabolism , Heart Rate , Insulin/blood , Ketones/blood , Liver/metabolism , Male
6.
Am J Physiol Endocrinol Metab ; 284(4): E695-707, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12626324

ABSTRACT

Epinephrine increases net hepatic glucose output (NHGO) mainly via increased gluconeogenesis, whereas glucagon increases NHGO mainly via increased glycogenolysis. The aim of the present study was to determine how the two hormones interact in controlling glucose production. In 18-h-fasted conscious dogs, a pancreatic clamp initially fixed insulin and glucagon at basal levels, following which one of four protocols was instituted. In G + E, glucagon (1.5 ng x kg(-1) x min(-1); portally) and epinephrine (50 ng x kg(-1) x min(-1); peripherally) were increased; in G, glucagon was increased alone; in E, epinephrine was increased alone; and in C, neither was increased. In G, E, and C, glucose was infused to match the hyperglycemia seen in G + E ( approximately 250 mg/dl). The areas under the curve for the increase in NHGO, after the change in C was subtracted, were as follows: G = 661 +/- 185, E = 424 +/- 158, G + E = 1178 +/- 57 mg/kg. Therefore, the overall effects of the two hormones on NHGO were additive. Additionally, glucagon exerted its full glycogenolytic effect, whereas epinephrine exerted its full gluconeogenic effect, such that both processes increased significantly during concurrent hormone administration.


Subject(s)
Epinephrine/blood , Glucagon/metabolism , Glucose/biosynthesis , Liver/metabolism , Alanine/blood , Alanine/pharmacokinetics , Animals , Blood Glucose/metabolism , Blood Pressure , Consciousness , Dogs , Fatty Acids, Nonesterified/blood , Female , Gluconeogenesis/physiology , Glycerol/blood , Glycogen/metabolism , Heart Rate , Ketones/blood , Lactic Acid/metabolism , Male
7.
Am J Physiol Endocrinol Metab ; 284(2): E291-301, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12531743

ABSTRACT

To determine the effects of an increase in lipolysis on the glycogenolytic effect of epinephrine (EPI), the catecholamine was infused portally into 18-h-fasted conscious dogs maintained on a pancreatic clamp in the presence [portal (Po)-EPI+FFA, n = 6] and absence (Po-EPI+SAL, n = 6) of peripheral Intralipid infusion. Control groups with high glucose (70% increase) and free fatty acid (FFA; 200% increase; HG+FFA, n = 6) and high glucose alone (HG+SAL, n = 6) were also included. Hepatic sinusoidal EPI levels were elevated (Delta 568 +/- 77 and Delta 527 +/- 37 pg/ml, respectively) in Po-EPI+SAL and EPI+FFA but remained basal in HG+FFA and HG+SAL. Arterial plasma FFA increased from 613 +/- 73 to 1,633 +/- 101 and 746 +/- 112 to 1,898 +/- 237 micromol/l in Po-EPI+FFA and HG+FFA but did not change in EPI+SAL or HG+SAL. Net hepatic glycogenolysis increased from 1.5 +/- 0.3 to 3.1 +/- 0.4 mg x kg(-1) x min(-1) (P < 0.05) by 30 min in response to portal EPI but did not rise (1.8 +/- 0.2 to 2.1 +/- 0.3 mg x kg(-1) x min(-1)) in response to Po-EPI+FFA. Net hepatic glycogenolysis decreased from 1.7 +/- 0.2 to 0.9 +/- 0.2 and 1.6 +/- 0.2 to 0.7 +/- 0.2 mg x kg(-1) x min(-1) by 30 min in HG+FFA and HG+SAL. Hepatic gluconeogenic flux to glucose 6-phosphate increased from 0.6 +/- 0.1 to 1.2 +/- 0.1 mg x kg(-1) x min(-1) (P < 0.05; by 3 h) and 0.7 +/- 0.1 to 1.6 +/- 0.1 mg x kg(-1) x min(-1) (P < 0.05; at 90 min) in HG+FFA and Po-EPI+FFA. The gluconeogenic parameters remained unchanged in the Po-EPI+SAL and HG+SAL groups. In conclusion, increased FFA markedly changed the mechanism by which EPI stimulated hepatic glucose production, suggesting that its overall lipolytic effect may be important in determining its effect on the liver.


Subject(s)
Blood Glucose/biosynthesis , Epinephrine/blood , Fatty Acids, Nonesterified/blood , Liver/metabolism , Sympathomimetics/blood , Amino Acids/metabolism , Animals , Blood Pressure , Consciousness , Dogs , Epinephrine/pharmacology , Fatty Acids, Nonesterified/pharmacology , Female , Glucagon/blood , Gluconeogenesis/physiology , Glycerol/metabolism , Heart Rate , Hydrocortisone/blood , Insulin/blood , Lactic Acid/metabolism , Liver Circulation , Male , Norepinephrine/blood , Sympathomimetics/pharmacology
8.
Am J Physiol Endocrinol Metab ; 282(2): E402-11, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11788373

ABSTRACT

The aim of this study was to determine the effect of high levels of free fatty acids (FFA) and/or hyperglycemia on hepatic glycogenolysis and gluconeogenesis. Intralipid was infused peripherally in 18-h-fasted conscious dogs maintained on a pancreatic clamp in the presence (FFA + HG) or absence (FFA + EuG) of hyperglycemia. In the control studies, Intralipid was not infused, and euglycemia (EuG) or hyperglycemia (HG) was maintained. Insulin and glucagon were clamped at basal levels in all four groups. The arterial blood glucose level increased by 50% in the HG and FFA + HG groups. It did not change in the EuG and FFA + EuG groups. Arterial plasma FFA increased by approximately 140% in the FFA + EuG and FFA + HG groups but did not change significantly either in the EuG or HG groups. Arterial glycerol levels increased by approximately 150% in both groups. Overall (3-h) net hepatic glycogenolysis was 196 +/- 26 mg/kg in the EuG group. It decreased by 96 +/- 20, 82 +/- 16, and 177 +/- 22 mg/kg in the HG, FFA + EuG, and FFA + HG groups, respectively. Overall (3-h) hepatic gluconeogenic flux was 128 +/- 22 mg/kg in the EuG group, but it was suppressed by 30 +/- 9 mg/kg in response to hyperglycemia. It was increased by 59 +/- 12 and 56 +/- 10 mg/kg in the FFA + EuG and FFA + HG groups, respectively. In conclusion, an increase in plasma FFA and glycerol significantly inhibited hepatic glycogenolysis and markedly stimulated hepatic gluconeogenesis.


Subject(s)
Fatty Acids, Nonesterified/pharmacology , Gluconeogenesis/drug effects , Glycogen/metabolism , Liver/metabolism , 3-Hydroxybutyric Acid/blood , 3-Hydroxybutyric Acid/metabolism , Amino Acids/blood , Amino Acids/metabolism , Animals , Arteries , Blood Glucose/metabolism , Dogs , Fatty Acids, Nonesterified/blood , Fatty Acids, Nonesterified/metabolism , Female , Glucose/metabolism , Glycerol/blood , Glycerol/metabolism , Kinetics , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...